Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
Earnings Data
Report Date
Jul 25, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
3.21Last Year’s EPS
2.65Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 25, 2025
|% Change Since: 3.76%
|Next Earnings Date:Jul 25, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in the Ex-Humira platform and increased guidance, driven by growth in immunology and neuroscience. However, there were significant challenges in Humira and aesthetics sales, with competitive pressures impacting Imbruvica. Overall, the company shows strong momentum despite these challenges.Company Guidance
During the AbbVie First Quarter 2025 Earnings Conference Call, the company reported an adjusted earnings per share of $2.46, surpassing the guidance midpoint by $0.10. Total net revenues for the quarter exceeded $13.3 billion, outperforming expectations by nearly $550 million. Notably, the ex-Humira platform exhibited a sales growth of over 21%, with strong performances across therapeutic areas such as immunology, neuroscience, oncology, and anesthetics. This robust performance has led AbbVie to raise its full-year adjusted earnings per share guidance by $0.10, now projected to be between $12.09 and $12.29. The company also highlighted its plans to invest over $10 billion in U.S. capital over the next decade to support volume growth and expand into new areas like obesity. Additionally, AbbVie anticipates a high single-digit revenue compound annual growth rate through 2029, underscoring its strong long-term growth prospects.Strong Ex-Humira Platform Performance
Ex-Humira platform delivered robust sales growth of more than 21%, with significant contributions from immunology, neuroscience, oncology, and anesthetics.
Increased Earnings and Revenue Guidance
Adjusted earnings per share guidance raised by $0.10 to between $12.09 and $12.29, with total net revenues of approximately $59.7 billion, an increase of $700 million.
Successful Launch and Growth in Immunology
Skyrizi and Rinvoq combined sales reached $5.1 billion, reflecting growth of more than 65%. Skyrizi achieved leading in-play share in ulcerative colitis in the US.
Neuroscience Revenue Growth
Neuroscience revenues grew by 17% on an operational basis, with VRAYLAR sales up 10.3% and migraine therapies delivering double-digit operational growth.
Oncology Segment Revenue Growth
Oncology revenues exceeded expectations with Venclexta global sales up 12.3% and emerging commercial portfolio in solid tumors showing promise.
---
ABBV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABBV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 25, 2025 | $180.37 | $186.06 | +3.15% |
| Jan 31, 2025 | $174.04 | $182.22 | +4.70% |
| Oct 30, 2024 | $185.96 | $197.79 | +6.36% |
| Jul 25, 2024 | $171.60 | $177.40 | +3.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AbbVie (ABBV) report earnings?
AbbVie (ABBV) is schdueled to report earning on Jul 25, 2025, TBA Not Confirmed.
What is AbbVie (ABBV) earnings time?
AbbVie (ABBV) earnings time is at Jul 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABBV EPS forecast?
ABBV EPS forecast for the fiscal quarter 2025 (Q2) is 3.21.
---
